{"id":"https://openalex.org/W2604333496","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.5005","title":"Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG","display_name":"Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG","publication_year":2004,"publication_date":"2004-07-15","ids":{"openalex":"https://openalex.org/W2604333496","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.5005","mag":"2604333496"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2004.22.14_suppl.5005","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.5005","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.14_suppl.5005","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037650974","display_name":"Jacobus Pfisterer","orcid":"https://orcid.org/0000-0001-9938-4689","observed_orcids":["https://orcid.org/0000-0001-9938-4689"]},"institutions":[{"id":"https://openalex.org/I4210095785","display_name":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie Studiengruppe","ror":"https://ror.org/01kjfnp05","country_code":"DE","type":"nonprofit","lineage":["https://openalex.org/I4210095785"]},{"id":"https://openalex.org/I4405267856","display_name":"Canadian Cancer Trials Group","ror":"https://ror.org/04rg46g58","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405267856"]}],"countries":["CA","DE"],"is_corresponding":false,"raw_author_name":"J. Pfisterer","raw_affiliation_strings":["AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, T\u00fcbingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, M\u00fcnchen, Germany; NCIC CTG, Kingston, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, T\u00fcbingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, M\u00fcnchen, Germany; NCIC CTG, Kingston, ON, Canada","institution_ids":["https://openalex.org/I4210095785","https://openalex.org/I4405267856"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087341200","display_name":"Marie Plante","orcid":"https://orcid.org/0000-0002-2298-7913","observed_orcids":["https://orcid.org/0000-0002-2298-7913"]},"institutions":[{"id":"https://openalex.org/I4210095785","display_name":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie Studiengruppe","ror":"https://ror.org/01kjfnp05","country_code":"DE","type":"nonprofit","lineage":["https://openalex.org/I4210095785"]},{"id":"https://openalex.org/I4405267856","display_name":"Canadian Cancer Trials Group","ror":"https://ror.org/04rg46g58","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405267856"]}],"countries":["CA","DE"],"is_corresponding":false,"raw_author_name":"M. Plante","raw_affiliation_strings":["AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, T\u00fcbingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, M\u00fcnchen, Germany; NCIC CTG, Kingston, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, T\u00fcbingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, M\u00fcnchen, Germany; NCIC CTG, Kingston, ON, Canada","institution_ids":["https://openalex.org/I4210095785","https://openalex.org/I4405267856"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058535647","display_name":"Ignace B. Vergote","orcid":"https://orcid.org/0000-0002-7589-8981","observed_orcids":["https://orcid.org/0000-0002-7589-8981"]},"institutions":[{"id":"https://openalex.org/I4210095785","display_name":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie Studiengruppe","ror":"https://ror.org/01kjfnp05","country_code":"DE","type":"nonprofit","lineage":["https://openalex.org/I4210095785"]},{"id":"https://openalex.org/I4405267856","display_name":"Canadian Cancer Trials Group","ror":"https://ror.org/04rg46g58","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405267856"]}],"countries":["CA","DE"],"is_corresponding":false,"raw_author_name":"I. Vergote","raw_affiliation_strings":["AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, T\u00fcbingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, M\u00fcnchen, Germany; NCIC CTG, Kingston, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, T\u00fcbingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, M\u00fcnchen, Germany; NCIC CTG, Kingston, ON, Canada","institution_ids":["https://openalex.org/I4210095785","https://openalex.org/I4405267856"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047695952","display_name":"Andreas du Bois","orcid":"https://orcid.org/0000-0002-8477-506X","observed_orcids":["https://orcid.org/0000-0002-8477-506X"]},"institutions":[{"id":"https://openalex.org/I4210095785","display_name":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie Studiengruppe","ror":"https://ror.org/01kjfnp05","country_code":"DE","type":"nonprofit","lineage":["https://openalex.org/I4210095785"]},{"id":"https://openalex.org/I4405267856","display_name":"Canadian Cancer Trials Group","ror":"https://ror.org/04rg46g58","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405267856"]}],"countries":["CA","DE"],"is_corresponding":false,"raw_author_name":"A. Du Bois","raw_affiliation_strings":["AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, T\u00fcbingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, M\u00fcnchen, Germany; NCIC CTG, Kingston, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, T\u00fcbingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, M\u00fcnchen, Germany; NCIC CTG, Kingston, ON, Canada","institution_ids":["https://openalex.org/I4210095785","https://openalex.org/I4405267856"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079834570","display_name":"Uwe A. G. Wagner","orcid":"https://orcid.org/0000-0002-5866-6273","observed_orcids":["https://orcid.org/0000-0002-5866-6273"]},"institutions":[{"id":"https://openalex.org/I4210095785","display_name":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie Studiengruppe","ror":"https://ror.org/01kjfnp05","country_code":"DE","type":"nonprofit","lineage":["https://openalex.org/I4210095785"]},{"id":"https://openalex.org/I4405267856","display_name":"Canadian Cancer Trials Group","ror":"https://ror.org/04rg46g58","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405267856"]}],"countries":["CA","DE"],"is_corresponding":false,"raw_author_name":"U. Wagner","raw_affiliation_strings":["AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, T\u00fcbingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, M\u00fcnchen, Germany; NCIC CTG, Kingston, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, T\u00fcbingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, M\u00fcnchen, Germany; NCIC CTG, Kingston, ON, Canada","institution_ids":["https://openalex.org/I4210095785","https://openalex.org/I4405267856"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113522075","display_name":"Holger W. Hirte","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095785","display_name":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie Studiengruppe","ror":"https://ror.org/01kjfnp05","country_code":"DE","type":"nonprofit","lineage":["https://openalex.org/I4210095785"]},{"id":"https://openalex.org/I4405267856","display_name":"Canadian Cancer Trials Group","ror":"https://ror.org/04rg46g58","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405267856"]}],"countries":["CA","DE"],"is_corresponding":false,"raw_author_name":"H. Hirte","raw_affiliation_strings":["AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, T\u00fcbingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, M\u00fcnchen, Germany; NCIC CTG, Kingston, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, T\u00fcbingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, M\u00fcnchen, Germany; NCIC CTG, Kingston, ON, Canada","institution_ids":["https://openalex.org/I4210095785","https://openalex.org/I4405267856"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032543018","display_name":"\u00c1ngel J. Lacave","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095785","display_name":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie Studiengruppe","ror":"https://ror.org/01kjfnp05","country_code":"DE","type":"nonprofit","lineage":["https://openalex.org/I4210095785"]},{"id":"https://openalex.org/I4405267856","display_name":"Canadian Cancer Trials Group","ror":"https://ror.org/04rg46g58","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405267856"]}],"countries":["CA","DE"],"is_corresponding":false,"raw_author_name":"A. J. Lacave","raw_affiliation_strings":["AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, T\u00fcbingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, M\u00fcnchen, Germany; NCIC CTG, Kingston, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, T\u00fcbingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, M\u00fcnchen, Germany; NCIC CTG, Kingston, ON, Canada","institution_ids":["https://openalex.org/I4210095785","https://openalex.org/I4405267856"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110029590","display_name":"A. St\u00e4hle","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095785","display_name":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie Studiengruppe","ror":"https://ror.org/01kjfnp05","country_code":"DE","type":"nonprofit","lineage":["https://openalex.org/I4210095785"]},{"id":"https://openalex.org/I4405267856","display_name":"Canadian Cancer Trials Group","ror":"https://ror.org/04rg46g58","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405267856"]}],"countries":["CA","DE"],"is_corresponding":false,"raw_author_name":"A. St\u00e4hle","raw_affiliation_strings":["AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, T\u00fcbingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, M\u00fcnchen, Germany; NCIC CTG, Kingston, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, T\u00fcbingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, M\u00fcnchen, Germany; NCIC CTG, Kingston, ON, Canada","institution_ids":["https://openalex.org/I4210095785","https://openalex.org/I4405267856"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052434013","display_name":"Rainer Kimmig","orcid":"https://orcid.org/0000-0003-1118-2199","observed_orcids":["https://orcid.org/0000-0003-1118-2199"]},"institutions":[{"id":"https://openalex.org/I4210095785","display_name":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie Studiengruppe","ror":"https://ror.org/01kjfnp05","country_code":"DE","type":"nonprofit","lineage":["https://openalex.org/I4210095785"]},{"id":"https://openalex.org/I4405267856","display_name":"Canadian Cancer Trials Group","ror":"https://ror.org/04rg46g58","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405267856"]}],"countries":["CA","DE"],"is_corresponding":false,"raw_author_name":"R. Kimmig","raw_affiliation_strings":["AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, T\u00fcbingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, M\u00fcnchen, Germany; NCIC CTG, Kingston, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, T\u00fcbingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, M\u00fcnchen, Germany; NCIC CTG, Kingston, ON, Canada","institution_ids":["https://openalex.org/I4210095785","https://openalex.org/I4405267856"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109832285","display_name":"E. A. Eisenhauer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095785","display_name":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie Studiengruppe","ror":"https://ror.org/01kjfnp05","country_code":"DE","type":"nonprofit","lineage":["https://openalex.org/I4210095785"]},{"id":"https://openalex.org/I4405267856","display_name":"Canadian Cancer Trials Group","ror":"https://ror.org/04rg46g58","country_code":"CA","type":"nonprofit","lineage":["https://openalex.org/I4405267856"]}],"countries":["CA","DE"],"is_corresponding":false,"raw_author_name":"E. Eisenhauer","raw_affiliation_strings":["AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, T\u00fcbingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, M\u00fcnchen, Germany; NCIC CTG, Kingston, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AGO OVAR, Kiel, Germany; NCIC CTG, Quebec City, PQ, Canada; EORTC GCG, Leuven, Belgium; AGO OVAR, Wiesbaden, Germany; AGO OVAR, T\u00fcbingen, Germany; NCIC CTG, Hamilton, ON, Canada; EORTC GCG, Oviedo, Spain; AGO OVAR, Karlsruhe, Germany; AGO OVAR, M\u00fcnchen, Germany; NCIC CTG, Kingston, ON, Canada","institution_ids":["https://openalex.org/I4210095785","https://openalex.org/I4405267856"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":64,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"22","issue":"14_suppl","first_page":"5005","last_page":"5005"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10668","display_name":"Endometrial and Cervical Cancer Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2729","display_name":"Obstetrics and Gynecology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":0.8989999890327454},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":1.0},{"id":"https://openalex.org/keywords/recurrent-ovarian-cancer","display_name":"recurrent ovarian cancer","score":0.984000027179718},{"id":"https://openalex.org/keywords/platinum-sensitive-relapse","display_name":"platinum-sensitive relapse","score":0.7820000052452087},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7039999961853027},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.5550000071525574},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.7289999723434448},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.75},{"id":"https://openalex.org/keywords/febrile-neutropenia","display_name":"febrile neutropenia","score":0.7879999876022339},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.7429999709129333},{"id":"https://openalex.org/keywords/treatment-related-mortality","display_name":"non-relapse mortality","score":0.32600000500679016},{"id":"https://openalex.org/keywords/red-blood-cell-transfusion","display_name":"red blood cell transfusion","score":0.5490000247955322},{"id":"https://openalex.org/keywords/sensory-neuropathy","display_name":"sensory neuropathy","score":0.49300000071525574},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.5189999938011169},{"id":"https://openalex.org/keywords/response-rate","display_name":"response rate","score":0.38999998569488525}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9539483785629272},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.8050487041473389},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.6724251508712769},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6716277003288269},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.6249149441719055},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.5741837620735168},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.5467984080314636},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.5156375169754028},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5135664939880371},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4721548557281494},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.42878082394599915},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.40726202726364136},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3348032832145691},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3255559206008911},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.2015368640422821}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2004.22.14_suppl.5005","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.5005","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.14_suppl.5005","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"doi:10.1200/jco.2004.22.90140.5005","doi":"https://doi.org/10.1200/jco.2004.22.90140.5005","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.90140.5005","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2104998982","https://openalex.org/W2055638608","https://openalex.org/W2133321103","https://openalex.org/W2590848442","https://openalex.org/W1969431083","https://openalex.org/W4385850019","https://openalex.org/W2367334422","https://openalex.org/W2766344346","https://openalex.org/W2155095895","https://openalex.org/W2042863555"],"abstract_inverted_index":{"5005":[0],"Background:":[1],"Most":[2],"patients":[3,363],"(pts)":[4],"with":[5,49,364],"OVCA":[6,53,362],"relapse.":[7],"ICON":[8],"4":[9,69],"-":[10],"AGO":[11],"OVAR":[12],"2.2":[13],"results":[14],"suggest":[15],"combination":[16,349],"C-based":[17],"therapy":[18],"may":[19],"be":[20],"superior":[21],"to":[22,37,65,342],"single":[23],"agent":[24],"C.":[25],"GC":[26,144,186,210,234,260,267,282,314],"is":[27],"a":[28,299],"feasible":[29],"less":[30],"neurotoxic":[31],"regimen":[32],"and":[33,76,103,109,117,146,159,163,169,238,273,315,336,356],"thus":[34],"of":[35,60,111,139,190,212,288,303,350],"interest":[36],"evaluate":[38],"in":[39,94,184,209,250,345,358],"this":[40,44,337],"setting.":[41],"Methods:":[42],"In":[43],"phase":[45],"III":[46],"trial":[47],"pts":[48,120,283],"platinum":[50,359],"sensitive":[51,360],"recurrent":[52,361],"(\u2265":[54],"6":[55,142],"months":[56],"after":[57],"the":[58,185],"end":[59],"primary":[61,87],"therapy)":[62],"were":[63,99,125,130,181,227,248],"randomized":[64],"receive":[66],"C":[67,79,147,156,162,279,322,353],"(AUC":[68,80],"d1)":[70,82],"plus":[71,352],"G":[72,174,351],"(1000":[73],"mg/m2":[74],"d1":[75],"8)":[77],"or":[78,203,370,373],"5":[81],"every":[83],"3":[84],"weeks.":[85],"The":[86,149,348],"objective":[88],"compared":[89],"progression":[90],"free":[91],"survival":[92,106],"(PFS)":[93],"both":[95,242,251],"arms.":[96],"Secondary":[97],"objectives":[98],"response":[100],"rate":[101],"(RR)":[102],"duration,":[104],"overall":[105],"(OS),":[107],"toxicity":[108],"quality":[110],"life":[112],"(QoL).":[113],"Results:":[114],"From":[115],"09/99":[116],"04/02,":[118],"356":[119],"(178":[121],"GC,":[122],"178":[123],"C)":[124,237],"randomized.":[126],"Both":[127],"study":[128,338],"arms":[129,252],"well":[131,217,292],"balanced":[132],"for":[133,143,155,161,166,171,173,241,256,266,278,313,321],"baseline":[134],"disease":[135],"characteristics.":[136],"Median":[137],"number":[138],"cycles":[140],"was":[141,153,205,268,308,339],"(0\u201310)":[145],"(0\u20139).":[148],"weekly":[150],"dose":[151],"intensity":[152],"98.2%":[154],"(C":[157],"arm)":[158],"96.2%":[160],"75.6%":[164],"(92.8%":[165],"d":[167],"1":[168],"63.4%":[170],"d8)":[172],"(GC":[175],"arm).":[176],"Grade":[177,244],"3/4":[178,245],"hematologic":[179],"toxicities":[180,247],"significant":[182],"higher":[183],"arm":[187],"(anemia":[188],"27.4%":[189],"pts.":[191,213],"vs.":[192,196,200,214,223,235,261],"8.0%,":[193],"neutropenia":[194,232],"70.3%":[195],"12.0%,":[197],"thrombocytopenia":[198],"34.9%":[199],"11.4%).":[201],"G-CSF":[202],"GM-CSF":[204],"more":[206],"often":[207],"used":[208],"(23.6%":[211],"10.1%)":[215],"as":[216,218,291,293],"red":[219],"cell":[220],"transfusions":[221],"(37.1%":[222],"14.6%).":[224],"Clinical":[225],"sequelae":[226],"similar":[228],"between":[229],"arms:":[230],"febrile":[231],"(1.1%":[233,259],"0%":[236],"infections":[239],"(0.6%":[240],"arms).":[243],"non-hematologic":[246],"infrequent":[249],"(<":[253],"5%),":[254],"especially":[255],"sensory":[257],"neuropathy":[258],"1.7%":[262],"C).":[263],"Overall":[264],"RR":[265],"47.2%":[269],"(95%":[270,275,318],"CI:":[271,276,319,326],"39.9\u201354.5%)":[272],"30.9%":[274],"24.1\u201337.7)":[277],"(p=":[280],"0.0016).":[281],"reported":[284],"significantly":[285,294],"faster":[286],"palliation":[287],"abdominal":[289],"symptoms":[290],"improved":[295],"global":[296],"QoL.":[297],"With":[298],"median":[300,306],"follow":[301],"up":[302],"13":[304],"months,":[305],"PFS":[307,355],"8.6":[309],"mo":[310,317],"(95%CI:":[311],"8.0\u20139.7)":[312],"5.8":[316],"5.2\u20137.1)":[320],"(HR":[323],"0.72":[324],"[95%":[325],"0.57\u20130.90],":[327],"p=":[328],"0.0038,":[329],"e=":[330],"311).":[331],"OS":[332],"data":[333],"are":[334],"immature":[335],"not":[340],"powered":[341],"detect":[343],"differences":[344],"OS.":[346],"Conclusion:":[347],"improves":[354],"QoL":[357],"acceptable":[365],"toxicity.":[366],"Author":[367],"Disclosure":[368],"Employment":[369],"Leadership":[371],"Consultant":[372],"Advisory":[374],"Stock":[375],"Ownership":[376],"Honoraria":[377],"Research":[378],"Funding":[379],"Expert":[380],"Testimony":[381],"Other":[382],"Remuneration":[383],"Bristol-Myers":[384,388],"Squibb;":[385,389],"Eli":[386,390,392],"Lilly":[387,391,393]},"counts_by_year":[{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2017-04-14T00:00:00"}